Dry Age-related Macular Degeneration study: OCU410
Official title Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD
ClinicalTrials.gov ID: NCT07770828
What this study is testing
What is OCU410?
OCU410 is an investigational biological treatment being studied for dry age‑related macular degeneration.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see if OCU410 is safe and works for treating geographic atrophy, a form of dry AMD.
- Who it's for
- Adults with dry age‑related macular degeneration and geographic atrophy.
- What's involved
- Participants will be randomly assigned to receive OCU410 or a control treatment and will have regular eye exams and safety checks.
- Time commitment
- The trial lasts several months with multiple clinic visits for treatment and monitoring.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 55 and older
You may be able to join if
- people 55 years of age or older at consent.
- BCVA of ≥25 ETDRS letters or more using Early Treatment Diabetic Retinopathy Study (ETDRS) chart (20/320 Snellen Equivalent) and ≤80 ETDRS Letters...
- Fundus autofluorescence (FAF) imaging shows: a)Total GA area ≥2.5 and ≤ 17.5 mm2 (1 to 7 disk areas [DA], respectively)
- people with history of CNV diagnosis (inactive) in the fellow eye for ≥2 years prior to Screening
- people who had prior treatment with an approved drug for AMD, e.g. Izervay® (avacincaptad pegol) or Syfovre® (pegcetacoplan injection) can be...
You likely can't join if
- Previous treatment with a gene-therapy or cell therapy product.
- GA due to causes other than AMD such as Stargardt disease, cone rod dystrophy or toxic maculopathies like Plaquenil maculopathy.
- Spherical equivalent of the refractive error demonstrating \> 6 diopters of myopia or an axial length \>26 mm, inability to fixate, uncontrolled...
- Any history or current evidence of exudative ("wet") AMD in the study eye including any evidence of retinal pigment epithelium rips, branch retinal...
- Presence of double-layer sign on SD-OCT, suggestive of subclinical macular neovascularization.
The study team makes the final eligibility decision.
Where it is enrolling
- McAllen, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 55 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at McAllen, Texas, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.